Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Cohort Study of Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy

NCT06276088 is registered in ClinicalTrials.gov with Nanfang Hospital, Southern Medical University as lead sponsor.

NCT NCT06276088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06276088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Cohort Study of Plasma and Tissue SAA1 Levels in Cancer Patients to Predict Hyperprogression of Immunotherapy
Lead sponsor
Nanfang Hospital, Southern Medical University
Phase
Observational
Overall status
Recruiting
Start date
February 18, 2024
Completion date
October 31, 2026
Enrollment
374 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

biomarker, hyperprogression, immunotherapy